# Gamida Cell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gamida-cell

- Industry: Biotechnology
- Headquarters: Jerusalem, Israel
- Website: www.gamida-cell.com
- Total disclosed funding: $46M
- Latest round: Series E (May 15, 2012)
- Investors on record: 5

## About

Gamida Cell Ltd., based in Israel, is a biotechnology company focused on developing innovative cell and immune therapies to treat hematologic malignancies.Gamida Cell specializes in advanced cell therapy solutions. Founded in 1998 in Jerusalem, Israel, the company has undergone strategic pivots to focus on allogeneic cell therapies. Abigail Jenkins currently serves as the CEO. Gamida Cell has completed a total of 18 funding deals, with the most recent being a Private Placement/FOLLOW ON in April 2023, raising USD 23.00 mn, which brought the total amount raised to USD 23.00 mn.Gamida Cell specializes in advanced cell and immune therapy technologies, focusing on the development of allogeneic cell therapy products aimed at treating hematologic malignancies. Central to their offerings is Omisirge® (omidubicel-onlv), a proprietary product that utilizes nicotinamide (NAM) technology to enhance and expand cells, ultimately aiming to provide potentially curative treatment options for patients who may not have access to matched allo-HSCT (hematopoietic stem cell transplantation). The company’s technology addresses significant medical needs in the oncology space, particularly for patients experiencing infusion reactions, graft versus host disease, engraftment syndrome, and graft failure. Gamida Cell's products primarily target healthcare institutions, including hospitals and specialized treatment centers within North America and Europe, where they are positioned to serve oncologists and hematologists responsible for managing complex cancer therapies.Gamida Cell’s revenue generation is primarily driven through the sale of its specialized cellular therapies, including its flagship product, Omisirge®. The firm engages in direct business transactions with healthcare providers and hospitals, establishing partnerships that facilitate the integration of their therapies into clinical practice. Transactions typically occur on a B2B basis, where healthcare institutions purchase treatment solutions based on patient needs and institutional protocols, often involving negotiated pricing agreements that reflect the value and complexity of the therapies provided. In the most recent fiscal year, Gamida Cell reported an EBITDA of USD -73.77 mn.Gamida Cell plans to leverage the USD 23.00 mn raised in its most recent funding round to support the launch of Omisirge, with an emphasis on expanding its portfolio with the development of GDA-201 aimed at broadening treatment options. The company is also targeting expansion into new markets, specifically aiming to enhance its presence in Europe and North America by the end of 2023. The funds will assist in facilitating these initiatives and aligning with the strategic goals for growth and market penetration.

## Funding rounds

- Series E, May 15, 2012, $10M — Auriga Partners, Israel Healthcare Ventures, Teva Pharmaceutical Industries, Denali Ventures
- Series D, Sep 27, 2006, $16M — Israel Healthcare Ventures, Teva Pharmaceutical Industries, Denali Ventures, Elscint BioMedical Ltd.
- Series C, Aug 1, 2005, $3.7M — Auriga Partners
- Series B, Oct 1, 2001, $9.6M — Auriga Partners
- Series A, May 1, 2000, $6.7M — Auriga Partners

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series A, Series B, Series C, Series E
- Israel Healthcare Ventures (https://capitalatlas.ai/funds/israel-healthcare-ventures) — Series D, Series E
- Teva Pharmaceutical Industries — Series D, Series E
- Denali Ventures (https://capitalatlas.ai/funds/denali-ventures) — Series D, Series E
- Elscint BioMedical Ltd. — Series D